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a  b  s  t  r  a  c  t
A total of 2484 target bacterial pathogens were collected (one per patient episode) from
patients  in 16 Latin American medical centers located in seven nations during 2011. Isolate
identity  was conﬁrmed at a coordinating laboratory and susceptibility testing was performed
for  ceftaroline and comparator agents according to reference broth microdilution methods.
A  total of 30.0% of isolates were from respiratory tract, 29.4% from skin and skin structure,
21.4%  from blood stream, 7.9% from urinary tract and 11.3% from other sites. Ceftaroline
was  active against Staphylococcus aureus (42.8% MRSA) with 83.6% of the isolates at ≤1 mg/L
and  all isolates at ≤2 mg/L (MIC5090, 0.25/2 mg/L). National MRSA rates ranged from a low
of  28.8% in Colombia to a high of 68.1% in Chile. All Streptococcus pyogenes and Streptococ-
cus  agalactiae were susceptible to ceftaroline (MIC50/90 values were at ≤0.015/≤0.015 mg/L for
both).  All Streptococcus pneumoniae were susceptible to ceftaroline, linezolid, tigecycline and
vancomycin. Susceptibility to ceftriaxone was at 88.4% (CLSI non-meningitis interpretive
criteria)  and 73.9% (CLSI meningitis interpretive criteria) for all S. pneumoniae. Ceftriaxone
susceptibility  was only at 33.3% (CLSI non-meningitis interpretive criteria) and 0.0% (CLSI
meningitis  interpretive criteria) for penicillin-intermediate (penicillin MIC, 4 mg/L) strains.
All  Haemophilus inﬂuenzae (29.4% -lactamase-positive) isolates were susceptible to ceftaro-
line,  amoxicillin–clavulanate, ceftriaxone, and levoﬂoxacin. For the Latin American region,
the  ESBL-phenotype rate was 37.6% for Escherichia coli and 53.3% for Klebsiella pneumoniae.
Ceftaroline  was not active against ESBL-phenotype strains but was active against >90.0%of  the non-ESBL-phenotype. The spectrum of activity of ceftaroline against pathogens from
Latin  America indicates that it merits further study for its potential use in the Latin American
region.
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eftaroline fosamil (the prodrug of the active metabolite cef-
aroline)  is a new cephalosporin approved in the USA in 2010
or  acute bacterial skin and skin structure infections and
ommunity-acquired bacterial pneumonia and in Europe in
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2012 for community-acquired pneumonia and complicated
skin  and soft tissue infections.1,2 It was shown that ceftaro-
line  fosamil was  non-inferior to comparator agents in clinical
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agent that exhibits broad in vitro activity against Staphylococcus
aureus including methicillin-resistant S. aureus (MRSA), Strepto-
coccus  pyogenes, Streptococcus pneumoniae, Haemophilus spp., and
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Enterobacteriaceae.7–13 Ceftaroline exhibits a level of binding
afﬁnity  for PBPs in S. aureus including PBP2a in MRSA and in S.
pneumoniae including PBP2B and 2X.7,8
Ceftaroline and comparator agent activities against
pathogens have been monitored since 2008 in the Assessing
Worldwide Antimicrobial Resistance Evaluation (AWARE)
Program.10–13 The program provides continuing longitudinal
data on antimicrobial activity in order to provide contempo-
rary  information. In this report, we  present the results of the
Latin  American regional surveillance program for 2484 tar-
get  pathogens from 16 medical centers from seven countries
collected  during 2011 from SENTRY as part of the AWARE pro-
gram.
Materials  and  methods
Organism  collection
A total of 2484 target bacterial pathogens (S. aureus, S.
pneumoniae, S. pyogenes, S. agalactiae, Group C strepto-
cocci, Haemophilus inﬂuenzae, Haemophilus parainﬂuenzae,
Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and
Morganella  morganii) were  collected (one per patient episode)
from  patients in Latin American medical centers during
2011.  Isolates were  obtained from specimens of patients with
respiratory  tract infections (30.0%), skin and skin structure
infections, e.g. wound swabs or aspirated pus, etc. (29.4%),
bloodstream infections (21.4%), urinary tract infections (7.9%),
and  other infection types (11.3%; includes bone/joint, central
nervous  system, ear/nose/throat, eye, genital tract, and intra-
abdominal  infections). Isolate identity was  conﬁrmed at the
coordinating  laboratory (JMI Laboratories, North Liberty, IA,
USA). Sixteen medical centers participated from seven nations
(nation  [number of medical centers]): Argentina (2), Brazil (5),
Chile  (2) Colombia (1), Mexico (3), Panama (1), and Venezuela
(2).
Susceptibility  testing
Bacterial isolates were  tested for susceptibility to ceftaro-
line  and comparator agents according to the reference broth
microdilution methods of the Clinical and Laboratory Stan-
dards  Institute (CLSI).14 Susceptibility interpretations were
based  on CLSI (M100-S23) or EUCAST (2013) criteria; in the
case  of tigecycline the USA-FDA drug package insert crite-
ria  were  used in lieu of CLSI criteria, as no CLSI interpretive
criteria for tigecycline exist.15–17 CLSI interpretive criteria for
S.  aureus for ceftaroline are susceptible, ≤1 mg/L; intermediate,
2  mg/L; resistant, ≥4 mg/L while EUCAST interpretive criteria
are  susceptible, ≤1 mg/L and resistant, >1 mg/L. Discussions
on  susceptibility presented in this report are based on CLSI
interpretations unless otherwise speciﬁed. Cation-adjusted
Mueller-Hinton broth (CA-MHB), supplemented with 2.5–5%
lysed  horse blood for streptococci, was  used for susceptibil-
ity  testing. For Haemophilus spp., Haemophilus Test Medium
14was  used. E. coli and Klebsiella spp. isolates were  grouped
as  “ESBL-phenotype” based on the CLSI screening criteria for
ESBL production, i.e. MIC  of ≥2 mg/L for ceftazidime or ceftria-
xone  or aztreonam.15 Concurrent quality control (QC) testing 1 4;1  8(2):187–195
was  performed. QC strains included: S. aureus ATCC 29213,
Enterococcus faecalis ATCC 29212, S. pneumoniae ATCC 49619, H.
inﬂuenzae  ATCC 49247 and 49766, E. coli ATCC 25922 and 35218,
and  Pseudomonas aeruginosa ATCC 27853. All QC results were
within  published CLSI ranges.15
Results
The following numbers of organisms were collected from the
16  participating medical centers: S. aureus (956), S. pneumo-
niae  (249), S. pyogenes (66), Streptococcus agalactiae (78), Group
C  streptococcus (5), H. inﬂuenzae (126), H. parainﬂuenzae (6),
E.  coli (518), K. pneumoniae (379), K. oxytoca (40), and M.  morganii
(61).  Thirty percent were  from respiratory tract, 29.4% from
skin  and skin structure, 21.4% from blood stream, 7.9% from
urinary  tract, and 11.3% from other sites.
Ceftaroline was  active against S. aureus with MICs for
83.6%  of the isolates at ≤1 mg/L and all isolates at ≤2 mg/L
(MIC50/90, 0.25/2 mg/L; Table 1). Ceftaroline was  four- to eight-
fold  more  active against MSSA (MIC50 and MIC90, 0.25 and
0.25  mg/L) than MRSA (MIC50 and MIC90, 1 and 2 mg/L). A total
of  42.8% of S. aureus were  MRSA (Tables 1 and 2). For MRSA,
the  MIC50/90 values for ceftaroline were 1/2 mg/L with 61.6%
of  MIC  values at ≤1 mg/L (Tables 1 and 2). Ceftaroline was
16-fold  more  active than ceftriaxone against MSSA (data not
shown).  By deﬁnition all MRSA are resistant to ceftriaxone and
all  other -lactams except for the anti-MRSA cephalosporin
ceftaroline.15,16 National MRSA rates ranged from a low of
28.8%  in Colombia to a high of 68.1% in Chile (Table 3). All S.
aureus  were susceptible to daptomycin, linezolid, tigecycline,
and  vancomycin (Table 2).
The overall susceptibility of S. aureus to ceftaroline was
83.6%  (Table 2). For MSSA, susceptibility to ceftaroline was
100.0%  and for MRSA it was  61.6% (Table 2). All ceftaroline
non-susceptible S. aureus isolates (16.4% of all S. aureus) were
MRSA  and exhibited a MIC value of 2 mg/L (intermediate by
CLSI  criteria, resistant by EUCAST criteria) (Table 1). MRSA
with  a ceftaroline MIC  at 2 mg/L were found in all sampled
countries and rates varied from country to country. The per-
cent  of MRSA isolates which exhibited a MIC of 2 mg/L are
listed  for each country in rank order: Columbia (6.7%), Mexico
(15.5%),  Argentina (35.5%), Brazil (39.8%), Venezuela (41.9%),
Panama  (47.8%) and Chile (83.9%) (data not shown). Isolates
with  a ceftaroline MIC  at 2 mg/L were found in respiratory, skin
and soft tissue, bloodstream, and other infection types.
All  S. pyogenes and S. agalactiae were  susceptible to cef-
taroline and MIC50/90 values were at ≤0.015/≤0.015 mg/L
(Tables 1 and 2). S. pyogenes was highly susceptible to many
other  agents including ceftriaxone, penicillin, daptomycin,
tigecycline, vancomycin and linezolid, each at 100.0% suscep-
tibility  (Table 2). However, susceptibility to tetracycline was
only  at 81.8% and erythromycin at 90.9% (Table 2). All isolates
were  susceptible to levoﬂoxacin based on CLSI criteria; how-
ever,  7.6% of isolates were non-susceptible to levoﬂoxacin
based on EUCAST criteria (Table 2). All S. agalactiae were
susceptible to all tested -lactams, as well as daptomycin,
linezolid, tigecycline and vancomycin (Table 2).
All  S. pneumoniae were susceptible to ceftaroline, line-


























Table 1 – Summary of ceftaroline activity tested against pathogen groups from Latin America (2011).
Organisms (no. tested) Number of isolates (cumulative %) inhibited at ceftaroline MIC (mg/L) of: MIC50 MIC90
≤0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 >32
Staphylococcus aureus
(956)
–  – 2 (0.2) 41 (4.5) 489 (55.6) 103 (66.4) 164 (83.6) 157 (100.0) – – – – – 0.25 2
MSSA (547) – – 2 (0.4) 41 (7.9) 485 (96.5) 19 (100.0) – – – – – – – 0.25 0.25
MRSA (409) – – – – 4 (1.0) 84 (21.5) 164 (61.6) 157 (100.0) – – – – – 1 2
Streptococcus pneumoniae
(249)
140  (56.2) 25  (66.3) 22  (75.1) 53  (96.4) 9  (100.0) –  – – – – – – – ≤0.015 0.12
Penicillin-susceptible
(MIC, ≤2 mg/L) (215)
140 (65.1) 25  (76.7) 22  (87.0) 27  (99.5) 1  (100.0) –  – – – – – – – ≤0.015 0.12
Penicillin-
intermediate (MIC,
4  mg/L) (33)
– – – 25 (75.8) 8 (100.0) – – – – – – – – 0.12 0.25
Penicillin-resistant
(MIC, ≥8 mg/L) (1)
– – – 1 (100.0) – – – – – – – – – 0.12 –
S. pyogenes (66) 65 (98.5) 1 (100.0) – – – – – – – – – – ≤0.015 ≤0.015
S. agalactiae (78) 71 (91.0) 7 (100.0) – – – – – – – – – – – ≤0.015 ≤0.015
Group C Streptococcus (5) 5 (100.0) – – – – – – – – – – – – ≤0.015 –
Haemophilus inﬂuenzae
(126)
96  (76.2) 25 (96.0) 3 (98.4) 2 (100.0) – – – – – – – – – ≤0.015 0.03
-Lactamase negative
(89)
76  (85.4) 12 (98.9) 1 (100.0) – – – – – – – – – – ≤0.015 0.03
-Lactamase positive
(37)
20  (54.1) 13 (89.2) 2 (94.6) 2 (100.0) – – – – – – – – – ≤0.015 0.06
Haemophilus
parainﬂuenzae (6)
5  (83.3) 1  (100.0) –  – – – – – – – – – – ≤0.015 –
Escherichia coli (518) 2 (0.4) 41 (8.3) 103 (28.2) 88 (45.2) 42 (53.3) 18 (56.8) 21 (60.8) 8 (62.4) 4 (63.1) 6 (64.3) 3 (64.9) 3 (65.4) 179 (100.0) 0.25 >32
Non-ESBL-phenotype
(323)
2 (0.6) 41 (13.3) 103 (45.2) 88 (72.4) 42 (85.4) 17 (90.7) 20 (96.9) 8 (99.4) 1 (99.7) 1 (100.0) – – – 0.12 0.5
ESBL-phenotype (195) – – – – – 1 (0.5) 1 (1.0) 0 (1.0) 3 (2.6) 5 (5.1) 3 (6.7) 3 (8.2) 179 (100.0) >32 >32
Klebsiella pneumoniae
(379)
1  (0.3) 13 (3.7) 81 (25.1) 50 (38.3) 16 (42.5) 8 (44.6) 5 (45.9) 4 (47.0) 2 (47.5) 4 (48.5) 3 (49.3) 9 (51.7) 183 (100.0) 32 >32
Non-ESBL-phenotype
(177)
1 (0.6) 13 (7.9) 81 (53.7) 50 (81.9) 16 (91.0) 8 (95.5) 5 (98.3) 3 (100.0) – – – – – 0.06 0.25
ESBL-phenotype (202) – – – – – – – 1 (0.5) 2 (1.5) 4 (3.5) 3 (5.0) 9 (9.4) 183 (100.0) >32 >32
Klebsiella oxytoca (40) – 1 (2.5) 7 (20.0) 9 (42.5) 8 (62.5) 0 (62.5) 0 (62.5) 0 (62.5) 0 (62.5) 0 (62.5) 2 (67.5) 1 (70.0) 12 (100.0) 0.25 >32
Non-ESBL-phenotype
(25)
– 1 (4.0) 7  (32.0) 9  (68.0) 8  (100.0) – – – – – – – – 0.12 0.25
ESBL-phenotype (15) –  – – – – – – – – – 2 (13.3) 1 (20.0) 12 (100.0) >32 >32
Morganella morganii (61) – 1 (1.6) 10 (18.0) 8 (31.1) 7 (42.6) 7 (54.1) 2 (57.4) 1 (59.0) 3 (63.9) 2 (67.2) 3 (72.1) 4 (78.7) 13 (100.0) 0.5 >32
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Table 2 – Activity of ceftaroline and comparator antimicrobial agents when tested against contemporary Gram-positive
pathogens from Latin American medical centers (2011).
Organism (no. tested/antimicrobial agents) MIC (mg/L) CLSIa EUCASTa
MIC50 MIC90 Range %S/%I/%R %S/%I/%R
S. aureus (956)
Ceftaroline 0.25 2 0.06–2 83.6/–/– 83.6/0.0/16.4
Oxacillin 0.5 >2 ≤0.25 to >2 57.2/0.0/42.8 57.2/0.0/42.8
Erythromycin 0.5 >16 ≤0.12 to >16 52.8/1.8/45.4 53.1/0.8/46.1
Clindamycin ≤0.25 >2 ≤0.25 to >2 66.6/0.1/33.3 66.4/0.2/33.4
Levoﬂoxacin 0.25 >4 ≤0.12 to >4 64.2/0.7/35.1 64.2/0.7/35.1
Moxiﬂoxacin ≤0.12 4 ≤0.12 to >4 64.4/7.3/28.3 64.4/7.3/28.3
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 98.2/0.0/1.8 98.2/0.2/1.6
Tetracycline ≤0.25 0.5 ≤0.25 to >8 92.9/0.7/6.4 91.1/1.5/7.4
Tigecyclineb 0.06 0.12 ≤0.03–0.25 100.0/–/– 100.0/0.0/0.0
Linezolid 1 2 0.25–2 100.0/0.0/0.0 100.0/0.0/0.0
Vancomycin 1 1 ≤0.12–2 100.0/0.0/0.0 100.0/0.0/0.0
Daptomycin 0.25 0.5 0.12–1 100.0/–/– 100.0/0.0/0.0
MRSA (409)
Ceftaroline 1 2 0.25–2 61.6/–/– 61.6/0.0/38.4
Erythromycin >16 >16 ≤0.12 to >16 16.6/0.0/83.4 16.6/0.0/83.4
Clindamycin >2 >2 ≤0.25 to >2 27.4/0.2/72.4 27.4/0.0/72.6
Levoﬂoxacin >4 >4 ≤0.12 to >4 21.8/0.7/77.5 21.8/0.7/77.5
Moxiﬂoxacin 2 >4 ≤0.12 to >4 22.0/15.7/62.3 22.0/15.7/62.3
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5 to >4 96.3/0.0/3.7 96.3/0.0/3.7
Tetracycline ≤0.25 2 ≤0.25 to >8 92.7/0.2/7.1 89.5/3.2/7.3
Tigecyclineb 0.06 0.12 ≤0.03–0.25 100.0/–/– 100.0/0.0/0.0
Linezolid 1 1 0.5–2 100.0/0.0/0.0 100.0/0.0/0.0
Vancomycin 1 1 0.5–2 100.0/0.0/0.0 100.0/0.0/0.0
Daptomycin 0.5 0.5 0.25–1 100.0/–/– 100.0/0.0/0.0
MSSA (547)
Ceftaroline 0.25 0.25 0.06–0.5 100.0/–/– 100.0/0.0/0.0
Erythromycin 0.25 >16 ≤0.12 to >16 79.9/3.1/17.0 80.4/1.3/18.3
Clindamycin ≤0.25 ≤0.25 ≤0.25 to >2 96.0/0.0/4.0 95.6/0.4/4.0
Levoﬂoxacin ≤0.12 0.25 ≤0.12 to >4 96.0/0.5/3.5 96.0/0.5/3.5
Moxiﬂoxacin ≤0.12 ≤0.12 ≤0.12 to >4 96.2/0.9/2.9 96.2/0.9/2.9
Trimethoprim/sulfamethoxazole ≤0.5 ≤0.5 ≤0.5–4 99.6/0.0/0.4 99.6/0.4/0.0
Tetracycline ≤0.25 0.5 ≤0.25 to >8 93.0/1.1/5.9 92.3/0.2/7.5
Tigecyclineb 0.06 0.06 ≤0.03–0.25 100.0/–/– 100.0/0.0/0.0
Linezolid 1 2 0.25–2 100.0/0.0/0.0 100.0/0.0/0.0
Vancomycin 1 1 ≤0.12–2 100.0/0.0/0.0 100.0/0.0/0.0
Daptomycin 0.25 0.5 0.12–1 100.0/–/– 100.0/0.0/0.0
Streptococcus pneumoniae (249)
Ceftaroline  ≤0.015 0.12 ≤0.015–0.25 100.0/–/– 100.0/0.0/0.0
Ceftriaxonec ≤0.06 2 ≤0.06 to >8 88.4/11.2/0.4 73.9/25.7/0.4
Ceftriaxoned ≤0.06 2 ≤0.06 to >8 73.9/14.5/11.6 –/–/–
Penicilline ≤0.06 4 ≤0.06–8 86.3/13.3/0.4 –/–
Penicillinf ≤0.06 4 ≤0.06–8 54.2/20.9/24.9 54.2/32.1/13.7
Amoxicillin/clavulanate ≤1 4 ≤1 to >8 87.6/4.8/7.6 –/–/–
Erythromycin ≤0.12 >16 ≤0.12 to >16 69.5/0.0/30.5 69.5/0.0/30.5
Clindamycin ≤0.25 >2 ≤0.25 to >2 82.3/0.4/17.3 82.7/0.0/17.3
Levoﬂoxacin 1 1 0.5 to >4 99.2/0.0/0.8 99.2/0.0/0.8
Moxiﬂoxacin ≤0.12 0.25 ≤0.12–4 99.2/0.0/0.8 99.2/0.0/0.8
Trimethoprim/sulfamethoxazole 1 >4 ≤0.5 to >4 47.0/12.8/40.2 51.8/8.0/40.2
Tetracycline 0.5 >8 ≤0.25 to >8 67.5/1.6/30.9 66.7/0.8/32.5
Tigecyclineb ≤0.03 0.06 ≤0.03–0.06 100.0/–/– –/–/–
Linezolid 1 1 0.25–2 100.0/–/– 100.0/0.0/0.0
Vancomycin 0.25 0.5 ≤0.12–1 100.0/–/– 100.0/0.0/0.0
Streptococcus pyogenes (66)
Ceftaroline  ≤0.015 ≤0.015 ≤0.015–0.03 100.0/–/– 100.0/0.0/0.0
Ceftriaxone ≤0.06 ≤0.06 ≤0.06–0.25 100.0/–/– 100.0/0.0/0.0
Penicillin ≤0.06 ≤0.06 ≤0.06–0.12 100.0/–/– 100.0/0.0/0.0
Erythromycin ≤0.12 0.25 ≤0.12 to >16 90.9/1.5/7.6 90.9/1.5/7.6
Clindamycin ≤0.25 ≤0.25 ≤0.25 to >2 95.5/0.0/4.5 95.5/0.0/4.5
Levoﬂoxacin 0.5 1 0.25–2 100.0/0.0/0.0 92.4/7.6/0.0
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Organism (no. tested/antimicrobial agents) MIC (mg/L) CLSIa EUCASTa
MIC50 MIC90 Range %S/%I/%R %S/%I/%R
Tetracycline ≤0.25 >8 ≤0.25 to >8 81.8/1.5/16.7 80.3/1.5/18.2
Tigecyclineb ≤0.03 ≤0.03 ≤0.03 100.0/–/– 100.0/0.0/0.0
Linezolid 1 1 0.5–1 100.0/–/– 100.0/0.0/0.0
Vancomycin 0.25 0.5 0.25–1 100.0/–/– 100.0/0.0/0.0
Daptomycin ≤0.06 0.12 ≤0.06–0.25  100.0/–/– 100.0/0.0/0.0
Streptococcus agalactiae (78)
Ceftaroline  ≤0.015 ≤0.015 ≤0.015–0.03 100.0/–/– 100.0/0.0/0.0
Ceftriaxone ≤0.06 0.12 ≤0.06–0.25 100.0/–/– 100.0/0.0/0.0
Penicillin ≤0.06 ≤0.06 ≤0.06–0.12 100.0/–/– 100.0/0.0/0.0
Ceftriaxone ≤0.06 0.12 ≤0.06–0.25 100.0/–/– 100.0/0.0/0.0
Erythromycin ≤0.12 2 ≤0.12 to >16 87.2/1.3/11.5 87.2/1.3/11.5
Clindamycin ≤0.25 ≤0.25 ≤0.25 to >2 96.2/0.0/3.8 96.2/0.0/3.8
Levoﬂoxacin 0.5 1 ≤0.12 to >4 98.7/0.0/1.3 96.2/2.5/1.3
Tetracycline >8 >8 ≤0.25 to >8 21.8/0.0/78.2 21.8/0.0/78.2
Tigecyclineb ≤0.03 ≤0.03 ≤0.03–0.06 100.0/–/– 100.0/0.0/0.0
Linezolid 1 1 0.5–1 100.0/–/– 100.0/0.0/0.0
Vancomycin 0.5 0.5 0.25–1 100.0/–/– 100.0/0.0/0.0
Daptomycin 0.25 0.25 ≤0.06–0.5 100.0/–/– 100.0/0.0/0.0
a Criteria as published by the CLSI15 and EUCAST.16
b USA-FDA breakpoints were applied (Tygacil Product Package Insert, 2011).17
c Criteria as published by the CLSI15 for ‘ceftriaxone (non-meningitis)’.
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anged from 47.0% to 69.5% (Table 2). Susceptibility to cef-
riaxone  was  at 88.4% (CLSI non-meningitis interpretive
riteria) or 73.9% (meningitis interpretive criteria) and at
3.9%  when applying EUCAST criteria for all S. pneumoniae
Table 2). Susceptibility to ceftriaxone was  only at 33.3%
non-meningitis interpretive criteria) and 0.0% when applying
ither  CLSI interpretive criteria for meningitis or EUCAST
riteria for penicillin-intermediate (penicillin MIC, 4 mg/L)
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Table 3 – Antimicrobial resistant phenotypes stratiﬁed by natio
Resistant phenotype Freque
All nations Argentina Bra
MRSA 42.8 (956) 54.5 (101) 30.7 
Pen-non-S (MIC ≥4 mg/L) S. pneumoniae 13.7 (249) 10.5 (38) 4.3 
-Lactamase-positive H. inﬂuenzae 29.4 (126) 34.5 (29) 28.3 
ESBL-phenotypea E. coli 37.6 (518) 22.0 (41) 18.9 
ESBL-phenotypea K. pneumoniae 53.3 (379) 57.1 (49) 52.2 
ESBL-phenotype deﬁned as MIC of ≥2 mg/L for ceftazidime or ceftriaxone gitis)’.
Brazil, Chile, Colombia and Panama (Table 3). Mexico at
37.5%  and Venezuela at 66.7% exhibited the two highest rates
(Table  3).
All  H. inﬂuenzae isolates were susceptible to ceftaro-
line, amoxicillin–clavulanate, ceftriaxone, and levoﬂoxacin
(Table 4). Applying EUCAST criteria, the susceptibility
rates for the above agents were 96.0, 88.9, 99.2 and
100.0%, respectively. Tigecycline susceptibility (86.5%) and
trimethoprim–sulfamethoxazole (61.1%) were  compromised
(Table 4). A total of 29.4% of isolates were -lactamase-positive
(Tables 1, 3 and 4). Of the three nations for which >20 H.
inﬂuenzae isolates were obtained, -lactamase-positive rates
were  27.3% (Chile), 28.3% (Brazil) and 34.5% (Argentina Table 3).
There were only six H. parainﬂuenzae, half of which were  resis-
tant  to trimethoprim–sulfamethoxazole and all ceftaroline
MIC  values were  at ≤0.03 mg/L (Table 1).
For  the Latin American region, the ESBL-phenotype rate
for  518 E. coli was 37.6% (Table 1). Only two nations
n.
ncy of occurrence in % (no. of isolates tested)
zil Chile Colombia Mexico Panama Venezuela
(368) 68.1 (91) 28.8 (52) 44.7 (246) 46.9 (49) 63.3 (49)
(115) 6.7 (30) 0 (9) 37.5 (32) 10.0 (10) 66.7 (15)
(60) 27.3 (22) 36.4 (11) 0 (4) 0 (0) 0 (0)
(159) 28.2 (71) 21.2 (33) 70.7 (164) 36.7 (30) 10.0 (20)
(159) 58.8 (34) 56.3 (16) 55.6 (81) 40.0 (20) 45.0 (20)
or aztreonam (CLSI, 2013).
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Table 4 – Activity of ceftaroline and comparator antimicrobial agents when tested against contemporary Gram-negative
pathogens from Latin American medical centers (2011).
Organism (no. tested/antimicrobial agents) MIC (mg/L) CLSIa EUCASTa
MIC50 MIC90 Range %S/%I/%R %S/%I/%R
H. inﬂuenzae (126)
Ceftaroline  ≤0.015 0.03 ≤0.015–0.12 100.0/–/– 96.0/–/4.0
Amoxicillin/clavulanate ≤1 2 ≤1–2 100.0/0.0/0.0 88.9/0.0/11.1
Ceftriaxone ≤0.06 ≤0.06 ≤0.06–0.5 100.0/–/– 99.2/0.0/0.8
Tetracycline 0.5 0.5 ≤0.12 to >16 98.4/0.0/1.6 98.4/0.0/1.6
Tigecyclineb 0.25 0.5 0.06–1 86.5/–/– –/–/–
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 61.1/3.2/35.7 61.1/0.8/38.1
Azithromycin 1 2 0.25 to >4 99.2/–/– 0.0/99.2/0.8
Levoﬂoxacin ≤0.12 ≤0.12 ≤0.12 100.0/–/– 100.0/0.0/0.0
ˇ-Lactamase positive (37)
Ceftaroline  ≤0.015 0.03 ≤0.015–0.06 100.0/–/– 89.2/–/10.8
Amoxicillin/clavulanate ≤1 ≤1 ≤1–2 100.0/0.0/0.0 91.0/0.0/9.0
Ceftriaxone ≤0.06 ≤0.06 ≤0.06–0.5 100.0/–/– 98.9/0.0/1.1
Tetracycline 0.5 0.5 ≤0.12 to >16 98.9/0.0/1.1 98.9/0.0/1.1
Tigecyclineb 0.25 0.5 0.06–1 –/–/– –/–/–
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 70.8/3.4/25.8 70.8/1.1/28.1
Azithromycin 1 2 0.25 to >4 98.9/–/– 0.0/98.9/1.1
Levoﬂoxacin ≤0.12 ≤0.12 ≤0.12 100.0/–/– 100.0/0.0/0.0
ˇ-Lactamase-negative (89)
Ceftaroline  ≤0.015 0.03 ≤0.015–0.06 100.0/–/– 98.9/–/1.1
Amoxicillin/clavulanate ≤1 ≤1 ≤1–2 100.0/0.0/0.0 91.0/0.0/9.0
Ceftriaxone ≤0.06 ≤0.06 ≤0.06–0.5 100.0/–/– 98.9/0.0/1.1
Tetracycline 0.5 0.5 ≤0.12 to >16 98.9/0.0/1.1 98.9/0.0/1.1
Tigecyclineb 0.25 0.5 0.06–1 –/–/– –/–/–
Trimethoprim/sulfamethoxazole ≤0.5 >4 ≤0.5 to >4 70.8/3.4/25.8 70.8/1.1/28.1
Azithromycin 1 2 0.25 to >4 98.9/–/– 0.0/98.9/1.1
Levoﬂoxacin ≤0.12 ≤0.12 ≤0.12 100.0/–/– 100.0/0.0/0.0
E. coli (518)
Ceftaroline 0.25 >32 ≤0.015 to >32 56.8/4.0/39.2 56.8/–/43.2
Ceftazidime 0.25 32 0.03 to >32 69.5/3.1/27.4 65.6/3.9/30.5
Piperacillin/tazobactam 2 32 ≤0.5 to >64 86.5/8.5/5.0 78.2/8.3/13.5
Tetracycline >8 >8 ≤0.25 to >8 40.2/0.1/59.7 –/–/–
Tigecyclineb 0.12 0.25 ≤0.03–1 100.0/0.0/0.0 100.0/0.0/0.0
Gentamicin ≤1 >8 ≤1 to >8 72.6/0.8/26.6 70.5/2.1/27.4
Ciproﬂoxacin 4 >4 ≤0.03 to >4 48.5/0.1/51.4 47.9/0.6/51.5
Levoﬂoxacin 4 >4 ≤0.12 to >4 49.0/2.4/48.6 48.8/0.2/51.0
Meropenem ≤0.06 ≤0.06 ≤0.06–0.25 100.0/0.0/0.0 100.0/0.0/0.0
Non-ESBL phenotype (323)
Ceftaroline  0.12 0.5 ≤0.015–8 90.7/6.2/3.1 90.7/–/9.3
Ceftazidime 0.12 0.25 0.03–1 100.0/0.0/0.0 100.0/0.0/0.0
Piperacillin/tazobactam 2 4 ≤0.5 to >64 94.7/2.2/3.1 93.8/0.9/5.3
Tetracycline 2 >8 0.5 to >8 52.9/0.4/46.7 –/–/–
Tigecyclineb 0.12 0.25 ≤0.03–1 100.0/0.0/0.0 100.0/0.0/0.0
Gentamicin ≤1 >8 ≤1 to >8 88.2/0.7/11.1 86.7/1.5/11.8
Ciproﬂoxacin ≤0.03 >4 ≤0.03 to >4 69.4/0.1/30.7 69.0/0.3/30.7
Levoﬂoxacin ≤0.12 >4 ≤0.12 to >4 70.1/2.5/27.4 69.8/0.3/29.9
Meropenem ≤0.06 ≤0.06 ≤0.06–0.12 100.0/0.0/0.0 100.0/0.0/0.0
ESBL-phenotype (195)
Ceftaroline  >32 >32 0.5 to >32 0.5/0.5/99.0 0.5/0.0/99.5
Ceftazidime 16 >32 0.5 to >32 19.0/8.2/72.8 8.7/10.3/81.0
Piperacillin/tazobactam 8 64 ≤0.5 to >64 72.8/19.0/8.2 52.3/20.5/27.2
Tetracycline >8 >8 ≤0.25 to >8 19.0/0.0/81.0 –/–/–
Tigecyclineb 0.12 0.25 0.06–1 100.0/0.0/0.0 100.0/0.0/0.0
Gentamicin >8 >8 ≤1 to >8 46.7/1.0/52.3 43.6/3.1/53.3
Ciproﬂoxacin >4 >4 ≤0.03 to >4 13.8/0.6/85.6 12.8/1.0/86.2
Levoﬂoxacin >4 >4 ≤0.12 to >4 14.4/2.0/83.6 14.4/0.0/85.6
Meropenem ≤0.06 ≤0.06 ≤0.06–0.25 100.0/0.0/0.0 100.0/0.0/0.0
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Organism (no. tested/antimicrobial agents) MIC (mg/L) CLSIa EUCASTa
MIC50 MIC90 Range %S/%I/%R %S/%I/%R
Klebsiella pneumoniae (379)
Ceftaroline  32 >32 ≤0.015 to >32 44.6/1.3/54.1 44.6/–/55.4
Ceftazidime 2 >32 0.03 to >32 54.6/4.8/40.6 48.8/5.8/45.4
Piperacillin/tazobactam 8 >64 ≤0.5 to >64 62.3/8.7/29.0  55.1/7.2/37.7
Tetracycline 2 >8 0.5 to >8 61.2/2.4/36.4 –/–/–
Tigecyclineb 0.25 1 0.12 to >4 97.9/1.8/0.3 94.7/3.2/2.1
Gentamicin ≤1 >8 ≤1 to >8 69.7/3.9/26.4 68.1/1.6/30.3
Ciproﬂoxacin 0.25 >4 ≤0.03 to >4 56.9/5.0/38.1 54.5/2.4/43.1
Levoﬂoxacin 0.5 >4 ≤0.12 to >4 63.9/1.5/34.6 62.0/1.9/36.1
Meropenem ≤0.06 4 ≤0.06 to >8 87.3/2.1/10.6 89.4/3.2/7.4
Non-ESBL phenotype (177)
Ceftaroline  0.06 0.25 ≤0.015–2 95.5/2.8/1.7 95.5/–/4.5
Ceftazidime 0.12 0.5 0.03–1 100.0/0.0/0.0 100.0/0.0/0.0
Piperacillin/tazobactam 2 8 ≤0.5 to >64 96.6/1.7/1.7 94.4/2.2/3.4
Tetracycline 1 >8 0.5 to >8 76.8/0.6/22.6 –/–/–
Tigecyclineb 0.25 0.5 0.12 to >4 98.3/1.1/0.6 97.2/1.1/1.7
Gentamicin ≤1 ≤1 ≤1 to >8 96.0/1.7/2.3 96.0/0.0/4.0
Ciproﬂoxacin ≤0.03 0.5 ≤0.03 to >4 94.9/0.6/4.5 94.4/0.5/5.1
Levoﬂoxacin ≤0.12 0.5 ≤0.12  to >4 95.5/0.5/4.0 94.9/0.6/4.5
Meropenem ≤0.06 ≤0.06  ≤0.06–0.12 100.0/0.0/0.0 100.0/0.0/0.0
ESBL-phenotype (202)
Ceftaroline  >32 >32 2 to >32 0.0/0.0/100.0 0.0/0.0/100.0
Ceftazidime 32 >32 0.5 to >32 14.9/8.9/76.2 4.0/10.9/85.1
Piperacillin/tazobactam >64 >64 2 to >64 32.2/14.8/53.0 20.8/11.4/67.8
Tetracycline 8 >8 0.5 to >8 47.5/4.0/48.5 –/–/–
Tigecyclinec 0.25 1 0.12–4 97.5/2.5/0.0 92.6/4.9/2.5
Gentamicin 8 >8 ≤1 to >8 46.5/6.0/47.5 43.6/2.9/53.5
Ciproﬂoxacin >4 >4 ≤0.03 to >4 23.4/8.9/67.7 19.4/4.0/76.6
Levoﬂoxacin >4 >4 ≤0.12 to >4 36.1/2.5/61.4 33.2/2.9/63.9
Meropenem ≤0.06 >8 ≤0.06 to >8 76.2/4.0/19.8 80.2/5.9/13.9
K. oxytoca (40)
Ceftaroline 0.25 >32 0.03 to >32 62.5/0.0/37.5 62.5/–/37.5
Ceftazidime 0.12 4 0.03 to >32 92.5/0.0/7.5 82.5/10.0/7.5
Piperacillin/tazobactam 2 >64 1 to >64 77.5/0.0/22.5 77.5/0.0/22.5
Tetracycline 1 4 ≤0.25 to >8 92.5/0.0/7.5 –/–/–
Tigecyclineb 0.12 0.25 0.06–2 100.0/0.0/0.0 97.5/2.5/0.0
Gentamicin ≤1 >8 ≤1 to >8 87.5/0.0/12.5 87.5/0.0/12.5
Ciproﬂoxacin ≤0.03 1 ≤0.03 to >4 92.5/2.5/5.0 87.5/5.0/7.5
Levoﬂoxacin ≤0.12 1 ≤0.12 to >4 95.0/0.0/5.0 92.5/2.5/5.0
Meropenem ≤0.06 ≤0.06 ≤0.06 100.0/0.0/0.0 100.0/0.0/0.0
Morganella morganii (61)
Ceftaroline  0.5 >32 0.03 to >32 54.1/3.3/42.6 54.1/–/45.9
Ceftazidime 0.25 16 0.03 to >32 78.7/3.3/18.0 67.2/11.5/21.3
Piperacillin/tazobactam ≤0.5 2 ≤0.5 to >64 96.7/1.7/1.6 95.1/1.6/3.3
Tetracycline >8 >8 0.5 to >8 31.1/3.3/65.6 –/–/–
Tigecyclineb 0.5 2 0.12–4 93.4/6.6/0.0 88.5/4.9/6.6
Gentamicin ≤1 >8 ≤1 to >8 63.9/6.6/29.5 59.0/4.9/36.1
Ciproﬂoxacin 1 >4 ≤0.03 to >4 54.1/3.3/42.6 47.5/6.6/45.9
Levoﬂoxacin 1 >4 ≤0.12 to >4 57.4/13.1/29.5 52.5/4.9/42.6







la Criteria as published by the CLSI15 and EUCAST.16
b USA-FDA breakpoints were applied (Tygacil Product Package Insert
emonstrated ESBL-phenotype rates of less than 20%
Venezuela [10.0%] and Brazil [18.9%]; Table 3). The highest
ates  were in Panama (36.7%) and Mexico (70.7%; Table 3). The
egional  ESBL-phenotype rate for K. pneumoniae (53.3%) was
igher  than the E. coli rate (Table 3). For K. pneumoniae, the
owest  ESBL-phenotype rates were  found in Panama (40.0%)).17
and  Venezuela (45.0%) with rates in the remaining ﬁve nations
ranging  from 52.2% to 58.8% (Table 3). All E. coli were  suscep-
tible  to meropenem and tigecycline (Table 4). Susceptibility to
piperacillin–tazobactam was at 86.5% (78.2% by EUCAST crite-
ria;  Table 4). However susceptibility of E. coli to the remaining
agents  ranged from a low 40.2% for tetracycline to a high 72.6%
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for gentamicin (Table 4). Susceptibilities were decreased fur-
ther for the ESBL-phenotype strains of E. coli, where for exam-
ple,  levoﬂoxacin susceptibility was  at 14.4% (Table 4). For K.
pneumoniae,  tigecycline was  the only agent tested which exhib-
ited  greater than 90% susceptibility (97.9%; 94.7% by EUCAST
criteria;  Table 4). As was  noted for E. coli, the ESBL-phenotype
strains of K. pneumoniae showed much  higher resistance rates
for  most other agents; the exception was  tigecycline, which
still  showed susceptibility at 97.5% (92.6% by EUCAST criteria;
Table  4). Ceftaroline was  not active against ESBL-phenotype
strains of E. coli and K. pneumoniae; however 90.7% of non-
ESBL-phenotype E. coli and 95.5% of non-ESBL-phenotype K.
pneumoniae  were  susceptible to ceftaroline (Table 4).
Discussion
Previous AWARE surveillance studies in the USA indicated
that  for S. aureus including MRSA the MIC90 for ceftaro-
line was  at 1 mg/L and the highest MIC  values occurred in
MRSA  at 2 mg/L.10,11,13 MRSA values at 2 mg/L only repre-
sented 2.8% of MIC  values for 9875 MRSA isolates collected
during 2008–2011.13 In the Canadian surveillance program
(CANWARD) with 15 sentinel hospital laboratories, the high-
est  MIC  value in the 2009 survey was  at 0.5 mg/L for MSSA
and  1 mg/L for MRSA.18 However, Farrell et al. showed that for
isolates  from 19 countries in Europe and the Mediterranean
region although the MIC90 for S. aureus was  1 mg/L, for MRSA,
11.2%  of isolates were at 2 mg/L.19 In this 2011 Latin Amer-
ican  surveillance program,  16.4% of all S. aureus and 38.4%
of  MRSA exhibited a MIC  value of 2 mg/L. As was  noted in
the  Europe and the Mediterranean region, there were  more
MRSA  isolates with MIC  values at 2 mg/L than were noted
in  North America. This may  be due to differences in circu-
lating  MRSA clones and would be reﬂected in the regional
and  local susceptibility patterns.20–22 For example, the high-
est  percentage of MRSA with ceftaroline MIC of 2 mg/L in our
study  was  observed in Chile (83.9%) where previous studies
had  shown that the Cordobes/Chilean clone predominates.22
This clone displays the staphylococcal cassette chromosome
mec  (SCCmec)  type I which was  shown to have a modal value
for  ceftaroline–avibactam of 2 mg/L compared to 1 mg/L for
SCCmec  types II and III and 0.5 mg/L for SCCmec type IV.21
Overall -streptococci were  highly susceptible to ceftaro-
line  and other commonly used agents. However, S. pneumoniae
exhibited decreased susceptibility to a number of agents. For
example,  the overall rate of penicillin-non-susceptibility for
S. pneumoniae (penicillin, MIC, ≥4 mg/L) in the Latin Ameri-
can  region was  at 13.7% and varied on a national basis, up
to  66.7% in Venezuela. Further, susceptibility of S. pneumoniae
to  ceftriaxone was  at 88.4% (CLSI non-meningitis interpretive
criteria) or 73.9% (CLSI meningitis interpretive criteria) for all S.
pneumoniae (Table 2). Ceftriaxone susceptibility was  decreased
even  more  for penicillin-non-susceptible strains. Ceftaroline,
which  exhibited 100.0% susceptibility to all S. pneumoniae, may
provide  a potential alternative when penicillin or ceftriaxone
non-susceptible isolates are a concern.
Ceftaroline was  active against non-ESBL-phenotype
Enterobacteriaceae; however as for third generation
cephalosporins, it was  not active against ESBL-phenotype 1 4;1  8(2):187–195
strains. As the ESBL-phenotype occurred frequently in the
Latin  American region and varied among individual nations
the  likelihood of encountering a ESBL-phenotype strain will
need  to be considered in determining the potential role for
ceftaroline.  Examples of variation in national rates in this
study  included ESBL-phenotype E. coli isolates ranging from
10.0%  (Venezuela) to 70.7% (Mexico) and for ESBL-phenotype
K.  pneumoniae national rates from 40.0% in Panama to 58.8%
in  Chile.
In summary, ceftaroline was  shown to have in vitro activity
against  Gram-positive and selected Gram-negative pathogens
isolated  from patients in the Latin American region during
2011.  The spectrum of activity for ceftaroline included key
pathogens, which are found in a variety of infections includ-
ing  community-acquired pneumonia and skin and soft tissue
infections.  This included potent activity against non-ESBL
producing E. coli and K. pneumoniae but a lack of activity
against MDR Gram-negative bacteria such as ESBL-producing
E.  coli and K. pneumonia, which occurred frequently in the
Latin  American region. The spectrum of activity of ceftaroline
against  pathogens isolated from patients in Latin American
medical centers indicates that it merits further study for its
potential  use in the region.
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